Assetmark Inc. lowered its stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 84.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 999 shares of the company’s stock after selling 5,492 shares during the period. Assetmark Inc.’s holdings in VanEck Pharmaceutical ETF were worth $86,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently made changes to their positions in PPH. Townsquare Capital LLC raised its holdings in shares of VanEck Pharmaceutical ETF by 3.8% in the 3rd quarter. Townsquare Capital LLC now owns 3,519 shares of the company’s stock worth $334,000 after acquiring an additional 130 shares during the last quarter. FMR LLC raised its holdings in shares of VanEck Pharmaceutical ETF by 12.5% in the 3rd quarter. FMR LLC now owns 1,905 shares of the company’s stock worth $181,000 after acquiring an additional 212 shares during the last quarter. NTV Asset Management LLC raised its holdings in shares of VanEck Pharmaceutical ETF by 3.6% in the 4th quarter. NTV Asset Management LLC now owns 7,709 shares of the company’s stock worth $665,000 after acquiring an additional 271 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of VanEck Pharmaceutical ETF in the 4th quarter worth about $29,000. Finally, Activest Wealth Management acquired a new stake in shares of VanEck Pharmaceutical ETF in the 4th quarter worth about $32,000.
VanEck Pharmaceutical ETF Price Performance
PPH opened at $91.85 on Friday. VanEck Pharmaceutical ETF has a fifty-two week low of $84.48 and a fifty-two week high of $99.51. The firm has a market capitalization of $573.14 million, a PE ratio of 30.55 and a beta of 0.72. The company’s 50-day moving average is $89.48 and its 200 day moving average is $91.26.
VanEck Pharmaceutical ETF Increases Dividend
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
See Also
- Five stocks we like better than VanEck Pharmaceutical ETF
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Basic Materials Stocks Investing
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.